Search company, investor...



Grant | Alive

Total Raised


Last Raised

$150K | 11 yrs ago

About Nanocytomics

NanoCytomics is developing novel, highly accurate, low-cost, non-invasive tests for use in primary care physicians' offices. The company intends to revolutionize the risk stratification of patients, helping physicians identify those likely to benefit from gold-standard diagnostic procedures as early as possible, when cancer treatments can be the most effective.

Headquarters Location

1801 Maple Ave

Evanston, Illinois, 60201,

United States

Missing: Nanocytomics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Nanocytomics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Nanocytomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Nanocytomics is included in 1 Expert Collection, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Nanocytomics Patents

Nanocytomics has filed 7 patents.

The 3 most popular patent topics include:

  • Cell biology
  • Pathology
  • Acetylcholinesterase inhibitors
patents chart

Application Date

Grant Date


Related Topics




Microscopy, Molecular biology, Solar cells, Mass spectrometry, Polymers


Application Date


Grant Date



Related Topics

Microscopy, Molecular biology, Solar cells, Mass spectrometry, Polymers



Latest Nanocytomics News

NanoCytomics Awarded $1.5 million NIH Grant for Further Investigation of its Lung Cancer Screening Test

Oct 5, 2016

Menssana Research Wins NIH Award for Rapid Point-of-Care Breath Test for Breast Cancer Preora Diagnostics Inc. , a privately held medical technology company developing low- cost and highly accurate cancer screening tests, today announced that NanoCytomics LLC, the product development company that licenses its technology to Preora for potential commercialization of cancer screening tests, has been awarded a $1,497,000 “Direct to Phase II” grant from the National Institutes of Health (NIH) for its lung cancer screening test. The NIH grant is for two years and does not require a follow-up application in order to receive the full amount of financial support. “This award will enable NanoCytomics to develop and optimize a regulatory-compliant, self-contained Partial Wave Spectroscopy (PWS) Nanocytology system,” said Preora Diagnostics President and CEO John W. Hart. “Although additional funding will be required for clinical studies and other prerequisite activities before we can bring our lung cancer screening test to the marketplace, it is an important milestone along our path to making dramatic improvements in cancer survival rates.” Hariharan Subramanian, PhD, co-founder and chief technology officer, NanoCytomics, added, “We appreciate the support that NIH continues to provide us through this grant. It allows us to validate the systems, protocols and nanocytology biomarkers that would maximize sensitivity to early-stage lung cancers. We intend to conduct these studies with 500 subjects, at least 160 of whom will have been previously diagnosed with early-stage lung cancer.” About Preora Diagnostics Preora Diagnostics Inc. is dedicated to helping people survive cancer through a proven, two-tiered approach to early detection. The company develops proprietary, low-cost, minimally invasive, highly sensitive and highly specific cancer screening tests using technology that detects and measures cellular changes at the nanoscale level. The screening tests are based on the proprietary Partial Wave Spectroscopy (PWS) Nanocytology platform, licensed exclusively by Preora through NanoCytomics, LLC and Northwestern University. For more information, visit About NanoCytomics, LLC Recognizing their shared values and their ability to collaborate effectively, Vadim Backman, PhD; Hariharan Subramanian, PhD; and Hemant Roy, MD formed NanoCytomics LLC in 2011 based on the PWS Nanocytology technology platform that emerged from Dr. Backman’s Biophotonics Laboratory at Northwestern University’s McCormick School of Engineering. Their resulting research efforts spawned a new field, nanocytology, which today is the foundation for the company’s new product development efforts to revolutionize early cancer detection. For the original version on PRWeb visit:

Nanocytomics Frequently Asked Questions (FAQ)

  • Where is Nanocytomics's headquarters?

    Nanocytomics's headquarters is located at 1801 Maple Ave, Evanston.

  • What is Nanocytomics's latest funding round?

    Nanocytomics's latest funding round is Grant.

  • How much did Nanocytomics raise?

    Nanocytomics raised a total of $150K.

  • Who are the investors of Nanocytomics?

    Investors of Nanocytomics include National Science Foundation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.